404 related articles for article (PubMed ID: 15684203)
1. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
4. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
Graham DJ; Campen D; Hui R; Spence M; Cheetham C; Levy G; Shoor S; Ray WA
Lancet; 2005 Feb 5-11; 365(9458):475-81. PubMed ID: 15705456
[TBL] [Abstract][Full Text] [Related]
6. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
7. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Mamdani M; Rochon P; Juurlink DN; Anderson GM; Kopp A; Naglie G; Austin PC; Laupacis A
Arch Intern Med; 2003 Feb; 163(4):481-6. PubMed ID: 12588209
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
9. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
10. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
11. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
14. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
16. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Hernández-Díaz S; Varas-Lorenzo C; García Rodríguez LA
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):266-74. PubMed ID: 16611201
[TBL] [Abstract][Full Text] [Related]
17. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
Brownstein JS; Sordo M; Kohane IS; Mandl KD
PLoS One; 2007 Sep; 2(9):e840. PubMed ID: 17786211
[TBL] [Abstract][Full Text] [Related]
18. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Howes LG; Krum H
Drug Saf; 2002; 25(12):829-35. PubMed ID: 12241124
[TBL] [Abstract][Full Text] [Related]
19. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
20. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE; Brophy JM; Zhang B
CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]